Joshua Allen - Chimerix Chief Imipridones
| CMRX Stock | USD 0.90 0.01 1.10% |
Insider
Joshua Allen is Chief Imipridones of Chimerix
| Address | 2505 Meridian Parkway, Durham, NC, United States, 27713 |
| Phone | 919 806 1074 |
| Web | https://www.chimerix.com |
Joshua Allen Latest Insider Activity
Tracking and analyzing the buying and selling activities of Joshua Allen against Chimerix stock is an integral part of due diligence when investing in Chimerix. Joshua Allen insider activity provides valuable insight into whether Chimerix is net buyers or sellers over its current business cycle. Note, Chimerix insiders must abide by specific rules, including filing SEC forms every time they buy or sell Chimerix'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Joshua Allen over six months ago Acquisition by Joshua Allen of 129878 shares of Trust Stamp subject to Rule 16b-3 | ||
Joshua Allen over six months ago Disposition of 341 shares by Joshua Allen of Trust Stamp subject to Rule 16b-3 | ||
Joshua Allen over a year ago Exercise or conversion by Joshua Allen of 3713 shares of Trust Stamp subject to Rule 16b-3 | ||
Joshua Allen over a year ago Acquisition by Joshua Allen of 24079 shares of Trust Stamp subject to Rule 16b-3 |
Chimerix Management Efficiency
The company has return on total asset (ROA) of (0.3022) % which means that it has lost $0.3022 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4859) %, meaning that it created substantial loss on money invested by shareholders. Chimerix's management efficiency ratios could be used to measure how well Chimerix manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.41 in 2024. Return On Capital Employed is likely to drop to -0.5 in 2024. At this time, Chimerix's Non Current Assets Total are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 316.1 K in 2024, whereas Total Assets are likely to drop slightly above 197 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| MBA MBA | Mereo BioPharma Group | 67 | |
| Richard MD | X4 Pharmaceuticals | 61 | |
| Karl MD | Achilles Therapeutics PLC | 57 | |
| Robert Coutts | Achilles Therapeutics PLC | 40 | |
| Weidong Zhong | Terns Pharmaceuticals | 58 | |
| Jaa Roberson | Day One Biopharmaceuticals | N/A | |
| Adam Zlotnick | Assembly Biosciences | N/A | |
| Kerry MD | Terns Pharmaceuticals | N/A | |
| Senthil Sundaram | Terns Pharmaceuticals | 46 | |
| Ian Critchley | Spero Therapeutics | N/A | |
| Nicole White | Assembly Biosciences | N/A | |
| Bronson Crouch | Instil Bio | 51 | |
| Lieping MD | NextCure | 67 | |
| Jackie Parkin | Mereo BioPharma Group | 66 | |
| MHROD SHRMSCP | Assembly Biosciences | N/A | |
| Ted Jenkins | Spero Therapeutics | N/A | |
| John Lewicki | Mereo BioPharma Group | 72 | |
| Julia Wilson | Achilles Therapeutics PLC | N/A | |
| Keith MD | X4 Pharmaceuticals | 53 | |
| MBA MD | Spero Therapeutics | 43 | |
| Solomon Langermann | NextCure | 64 | |
Management Performance
| Return On Equity | -0.49 | ||||
| Return On Asset | -0.3 |
Chimerix Leadership Team
Elected by the shareholders, the Chimerix's board of directors comprises two types of representatives: Chimerix inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Chimerix. The board's role is to monitor Chimerix's management team and ensure that shareholders' interests are well served. Chimerix's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Chimerix's outside directors are responsible for providing unbiased perspectives on the board's policies.
| MD MBA, Chief Officer | ||
| Michael MBA, President CEO | ||
| David CPA, Exec Officer | ||
| Joshua Allen, Chief Imipridones | ||
| Dr MBA, Chief Officer | ||
| Michael Alrutz, interim CEO, Senior Vice President General Counsel | ||
| Pablo MD, Head Affairs | ||
| Roy Ware, Chief Manufacturing and Technology Officer | ||
| Thomas Riga, Chief Officer | ||
| Dr JD, General VP | ||
| Randall Lanier, Chief Science Officer | ||
| Michelle LaSpaluto, Chief Officer |
Chimerix Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Chimerix a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.49 | ||||
| Return On Asset | -0.3 | ||||
| Operating Margin | (953.58) % | ||||
| Current Valuation | (54.64 M) | ||||
| Shares Outstanding | 89.94 M | ||||
| Shares Owned By Insiders | 6.62 % | ||||
| Shares Owned By Institutions | 45.90 % | ||||
| Number Of Shares Shorted | 1.52 M | ||||
| Price To Earning | (3.43) X | ||||
| Price To Book | 0.60 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Chimerix Stock Analysis
When running Chimerix's price analysis, check to measure Chimerix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Chimerix is operating at the current time. Most of Chimerix's value examination focuses on studying past and present price action to predict the probability of Chimerix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Chimerix's price. Additionally, you may evaluate how the addition of Chimerix to your portfolios can decrease your overall portfolio volatility.